Scinai Immunotherapeutics (SCNI) Receivables (2015 - 2026)
Scinai Immunotherapeutics (SCNI) posted Receivables of $500.0 million for Q1 2026, up 105.76% sequentially from $243.0 million in Q4 2025.
Scinai Immunotherapeutics (SCNI) Receivables (2015 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Receivables for 12 years, with the latest figure at $500.0 million in Q1 2026.
- Quarterly Receivables changed N/A year-over-year to $500.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $500.0 million (changed N/A YoY) and the FY2025 annual result came in at $243.0 million, up 81994.59% from the prior year.
- Receivables improved to $500.0 million in Q1 2026 per SCNI's latest filing, from $243.0 million in the prior quarter.
- Over five years, Receivables peaked at $500.0 million in Q1 2026 and troughed at $73000.0 in Q1 2022.
- A 5-year average of $68.3 million and a median of $443000.0 in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2025: Receivables slumped 99.99% in 2022, then surged 81994.59% in 2025.
- Over 5 years, Receivables stood at $298000.0 in 2022, then jumped by 97.65% to $589000.0 in 2023, then slumped by 49.75% to $296000.0 in 2024, then soared by 81994.59% to $243.0 million in 2025, then surged by 105.76% to $500.0 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $500.0 million, $243.0 million, and $375000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Scinai Immunotherapeutics | 1.08 Mn | -3.11 Bn | -1.12 Mn | 150.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 500.00 Mn |
| Dec 31, 2025 | 243.00 Mn |
| Jun 30, 2025 | 375,000.00 |
| Dec 31, 2024 | 296,000.00 |
| Sep 30, 2024 | 448,000.00 |
| Jun 30, 2024 | 443,000.00 |
| Dec 31, 2023 | 589,000.00 |
| Jun 30, 2023 | 5.97 Mn |
| Sep 30, 2022 | 298,000.00 |
| Jun 30, 2022 | 294,000.00 |
| Mar 31, 2022 | 73,000.00 |
| Dec 31, 2021 | 651,000.00 |
| Sep 30, 2021 | 442,000.00 |
| Jun 30, 2021 | 2.64 Bn |
| Mar 31, 2021 | 481.00 Mn |
| Dec 31, 2020 | 1.20 Bn |
| Sep 30, 2020 | 851,000.00 |
| Jun 30, 2020 | 2.47 Bn |
| Mar 31, 2020 | 1.54 Bn |
| Dec 31, 2019 | 190,000.00 |